产品说明书
Cefoxitin sodium
 |
同义名 : | 头孢西丁 钠盐 ;MK-306;Cenomycin;Merck Sharp and Dohme Brand of Cefoxitin Sodium;Merck Frosst Brand of Cefoxitin Sodium;Merck Brand of Cefoxitin Sodium;Sodium, Cefoxitin;MSD Brand of Cefoxitin Sodium;Cefoxitin sodium salt;Merxin;Farmoxin;Betacef;Cefoxitin (sodium salt) |
| CAS号 : | 33564-30-6 | |
| 货号 : | A125671 | |
| 分子式 : | C16H16N3NaO7S2 | |
| 纯度 : | 98% | |
| 分子量 : | 449.434 | |
| MDL号 : | MFCD00079042 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(233.63 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(222.5 mM) |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Cefoxitin (Sodium) is a beta-lactam antibiotic derived from cephamycin C, a naturally occurring substance produced by Streptomyces lactamdurans. Its resistance to destruction by beta-lactamases results in a broad spectrum of antibacterial activity which includes anaerobic as well as Gram-positive and Gram-negative aerobic bacteria, including many resistant to cephalothin and other cephalosporins[3]. Shenqi Fuzheng injection combined with cefoxitin sodium after cesarean section can effectively reduce the postoperative maternal body temperature and promote the recovery of maternal gastrointestinal function, which is conducive to the repair of uterus, further correct anemia after cesarean section and prevent postpartum infection[4]. Cefoxitin sodium was shown to maintain 90% of its initial concentration in aqueous solution for 40 hours at room temperature (25 °C) and about 30 days at 5 °C[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03053401 | Post-operative Pain ... 展开 >> Quadriceps Muscle Strength 收起 << | Not Applicable | Recruiting | June 30, 2019 | United States, Ohio ... 展开 >> Akron Children's Hospital Recruiting Akron, Ohio, United States, 44308 Contact: Rami E Karroum, MD 330-543-8823 rkarroum@chmca.org Contact: Ibrahim Farid, MD 330-543-8823 ifarid@chmca.org Sub-Investigator: Ibrahim Farid, MD Sub-Investigator: Paul Fleissner, MD Sub-Investigator: Elizabeth Kendrick, MSN,RN Sub-Investigator: Jonathan Klein, DO Sub-Investigator: George Youssef, MD 收起 << |
| NCT00726622 | Colorectal Cancer | Phase 3 | Active, not recruiting | - | - |
| NCT00719303 | Fallopian Tube Clear Cell Aden... 展开 >>ocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Malignant Ovarian Brenner Tumor Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Primary Peritoneal Serous Adenocarcinoma Stage IIA Fallopian Tube Cancer AJCC v6 and v7 Stage IIA Ovarian Cancer AJCC V6 and v7 Stage IIB Fallopian Tube Cancer AJCC v6 and v7 Stage IIB Ovarian Cancer AJCC v6 and v7 Stage IIC Fallopian Tube Cancer AJCC v6 and v7 Stage IIC Ovarian Cancer AJCC v6 and v7 Stage IIIA Fallopian Tube Cancer AJCC v7 Stage IIIA Ovarian Cancer AJCC v6 and v7 Stage IIIA Primary Peritoneal Cancer AJCC v7 Stage IIIB Fallopian Tube Cancer AJCC v7 Stage IIIB Ovarian Cancer AJCC v6 and v7 Stage IIIB Primary Peritoneal Cancer AJCC v7 Stage IIIC Fallopian Tube Cancer AJCC v7 Stage IIIC Ovarian Cancer AJCC v6 and v7 Stage IIIC Primary Peritoneal Cancer AJCC v7 Stage IV Fallopian Tube Cancer AJCC v6 and v7 Stage IV Ovarian Cancer AJCC v6 and v7 Stage IV Primary Peritoneal Cancer AJCC v7 Undifferentiated Fallopian Tube Carcinoma Undifferentiated Ovarian Carcinoma 收起 << | Phase 3 | Recruiting | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.23mL 0.45mL 0.22mL |
11.13mL 2.23mL 1.11mL |
22.25mL 4.45mL 2.23mL |
| 参考文献 |
|---|